GlobeImmune, Inc : GlobeImmune to Present at 12th Annual Needham Healthcare Conference

 GlobeImmune, Inc : GlobeImmune to Present at 12th Annual Needham Healthcare
                                  Conference

LOUISVILLE, Colo., April 18,  2013 - GlobeImmune,  Inc., today announced  that 
Timothy C. Rodell, M.D., president and chief executive officer of GlobeImmune,
will present at the 12th Annual Needham Healthcare Conference at 2:20 p.m. EDT
on Tuesday, April 30, at The Westin New York Grand Central Hotel in New  York. 
Dr. Rodell will provide  an update on the  company's Tarmogen^® platform  and 
product  candidates,  including  GI-4000  for  the  treatment  of  Ras-mutated 
cancers,  GI-6207  for  cancers  expressing  carcinoembryonic  antigen  (CEA), 
GI-6301 for  cancers expressing  the brachyury  protein and  GI-13020 for  the 
treatment of chronic hepatitis B infection.

About GlobeImmune

GlobeImmune is a biopharmaceutical company focused on developing products  for 
the treatment  of cancer  and  infectious diseases  based on  its  proprietary 
Tarmogen  platform.  Tarmogens  activate  the  immune  system  by  stimulating 
cellular immunity,  known  as T  cell  immunity, in  contrast  to  traditional 
vaccines that predominately stimulate antibody production. To date,  Tarmogen 
product candidates have been generally  well tolerated in clinical trials  for 
multiple disease indications and are  efficient to manufacture. In May  2009, 
the company entered  into a collaboration  agreement with Celgene  Corporation 
focused  on  the  discovery,  development  and  commercialization  of  product 
candidates for the treatment of cancer. In October 2011, the company  entered 
into a  worldwide,  strategic collaboration  with  Gilead Sciences,  Inc.,  to 
develop Tarmogens  for the  treatment of  chronic hepatitis  B infection.  For 
additional   information,   please    visit   the    company's   website    at 
www.globeimmune.com.

                                     ###

GlobeImmune Contact:
Kirk Christoffersen
Senior Director Corporate Development
T: 303-625-2777
information@globeimmune.com

INVESTOR CONTACT:
Susan Noonan
S.A. Noonan Communications, LLC
T: 212-966-3650
susan@sanoonan.com

Media Contacts:
Lena Evans or Tony Russo, Ph.D.
Russo Partners, LLC
T: 212-845-4262 or 212-845-4251
lena.evans@russopartnersllc.com
tony.russo@russopartnersllc.com

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: GlobeImmune, Inc via Thomson Reuters ONE
HUG#1693969
 
Press spacebar to pause and continue. Press esc to stop.